Hearts and Minds Investments Limited Overview
Hearts and Minds Investments is a philanthropic listed investment company that offers Australian investors a concentrated, high-conviction portfolio of global equities without charging management or performance fees. Instead, its selected fund managers contribute their best ideas pro bono, and the company donates the equivalent of 1.5% of net tangible assets each year to Australian medical research organisations. Roughly 65% of the portfolio follows the ongoing top picks of a panel of Core Fund Managers (five at 30 June 2026: Caledonia, Magellan Investment Partners, Munro Partners, Prusik and TDM Growth Partners), and about 35% follows the annual stock pitches made at the Sohn Hearts & Minds Investment Leaders Conference, held for up to 12 months. With net assets of about A$774 million, a four-person executive team, an unpaid board, a progressive fully franked dividend policy and A$96.1 million in cumulative medical research donations alongside the conference, HM1 sits at the intersection of active global equities and structured philanthropy.
Company's own description (paraphrased from FY2026 Annual Report)
The Directors' Report describes HM1's principal activity as providing a concentrated investment portfolio of the highest conviction ideas from selected fund managers while also supporting Australian medical research organisations, and states that no change to this activity occurred or is expected. The Chair and Managing Director's letter frames HM1 as born from the investment and philanthropic vision of the Sohn Hearts & Minds Conference, with a "dual mission" of investment performance and social impact. The company's website describes the portfolio as 25–35 carefully chosen securities, actively managed by the Chief Investment Officer under Investment Committee oversight.
Independent characterisation
HM1 is a closed-end, internally administered, externally advised (but not externally managed) global equity vehicle. Its economic engine is the change in market value of roughly 25–30 listed and (minimally) unlisted equities, plus dividends received. It has no operating business, no customers in the conventional sense, no debt and no goodwill. Its "revenue" under Australian Accounting Standards is total investment income — realised and unrealised gains/losses on financial assets and foreign exchange plus dividends — which is inherently volatile and can be negative.
The distinctive feature is its cost structure. A conventional global equity LIC of HM1's size would typically pay a base management fee of roughly 1–1.5% of assets plus performance fees to an external manager. HM1 instead pays nothing to its managers (the company estimates fees forgone at A$12.4 million in FY2026) and directs an approximately equivalent sum (1.5% of average NTA, A$11.5 million expensed in FY2026) to medical research. Shareholders therefore bear an all-in cost similar to a conventional active fund, but the benefit accrues to charitable research rather than to manager profits. Non-donation operating costs (staff, administration, listing) are very low at roughly 0.28% of average equity in FY2026.
Revenue model mix
| Component of total investment income (AUD Mn) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Net realised gains on financial assets (FVTPL) | -71.49 | 18.93 | 56.05 | 79.59 |
| Net unrealised gains on financial assets (FVTPL) | 121.67 | 58.44 | 96.70 | -6.34 |
| Net realised FX gains | 2.18 | -9.30 | -9.44 | 6.00 |
| Net unrealised FX gains | -0.14 | 8.28 | 13.24 | -9.82 |
| Dividend income (net of withholding tax) | 5.35 | 7.01 | 8.58 | 9.88 |
| Interest, sundry and other income | 0.01 | 0.01 | 0.35 | 0.01 |
| Total investment income | 57.58 | 83.37 | 165.48 | 79.32 |
Source: FY2024 and FY2026 Statements of Comprehensive Income. Note: gains on investments made before 12 October 2021 that are classified at fair value through other comprehensive income (FVTOCI) bypass this line and flow through OCI.
Mix characterisation: "Product vs service vs subscription vs licensing" is not applicable. Income is approximately 85–95% capital gains/losses (realised and unrealised, including FX) and 5–15% dividend income in normal years; dividends were 12.5% of total investment income in FY2026 and 5.2% in FY2025.
Value-chain position and "customers"
Capital providers (shareholders): predominantly Australian retail and high-net-worth investors, SMSFs and philanthropic foundations (e.g., Paul Ramsay Foundation holds 4.27 million shares). Shareholders value franking credits — the company's dividend policy is explicitly designed to release franking credits.
Idea suppliers (pro bono): Core Fund Managers and annual Conference Fund Managers.
Beneficiaries: 21 Australian medical research organisations listed in the FY2026 Medical Research Report.
Service providers: Citco (administration), Boardroom (registry and company secretarial), Pitcher Partners (audit), JP Morgan (custody), many on pro bono or discounted terms per the FY2026 Chair's letter.
End-markets
HM1 invests in global listed equities. At 30 June 2026, the portfolio's currency exposure was 68% USD, 15% HKD, 10% EUR, 4% CAD, with the balance in AUD (FY26 AR Note 13). Sector exposure at FY2026 skewed to semiconductors and AI infrastructure (TSMC, Nvidia, ACM Research), consumer/retail, energy/resources (Cameco, SLB, Steel Dynamics), Asian conglomerates/financials (CK Hutchison, Swire Pacific, AIA) and a residual software sleeve (Microsoft, SAP, Monday.com, BlackLine).
Strategy
Stated strategy (themes from FY2026 Annual Report, paraphrased)
-
Dual mission: deliver investment performance and enduring social impact via medical research funding.
-
Best-ideas access: expose investors to the highest-conviction ideas of selected managers, several not otherwise accessible to Australian retail investors.
-
Style diversification: avoid dependence on any single manager's philosophy by blending multiple Core and Conference managers.
-
Medium-term horizon: target attractive shareholder returns over five years or more.
-
Full investment: remain fully invested subject to a cash buffer.
-
Discount narrowing: the Board states it is committed to narrowing the share price discount to NTA.
-
Progressive fully franked dividends: subject to profit reserves and franking balance; policy (Aug 2025) to add 0.5c per share each half-year.
Strategic initiatives (last 24 months)
| Initiative | Date | Description | Status / target |
|---|---|---|---|
| Portfolio management automation | H1 2025 | CEO Jollie's operating-model review implemented a system to automate and improve portfolio management | Completed; enabled leaner structure |
| Lean leadership model | May–Jun 2025 | Full-time CEO replaced with part-time MD | Implemented; KMP cost fell from A$1.09m (FY25) to A$0.49m (FY26) |
| Progressive dividend policy | Aug 2025 | +0.5c per share every six months | 9.0c (Oct 2025), 9.5c (Apr 2026), 10.0c (Oct 2026) delivered |
| Offshore Core manager | Sep 2025 | Prusik Investment Management added (Asia ex-Japan) | Strong first year per FY26 AR |
| Core manager panel rationalisation | FY2025–FY2026 | Panel reduced from seven (Caledonia, Cooper, Magellan, Munro, Regal, TDM, Tribeca at FY24) to five (Caledonia, Magellan, Munro, Prusik, TDM) | Exit dates for Cooper, Regal, Tribeca not disclosed in sources reviewed |
| Plato red-flag risk screen | Announced Aug 2026 | Plato Asset Management sharing (pro bono) a proprietary system scoring stocks on 150+ categories (forensic accounting, governance, remuneration, management behaviour) to exclude problematic stocks | Being integrated; further detail promised in coming months |
| Conference internationalisation | 2,026 | First offshore Sohn Hearts & Minds Conference in Queenstown, NZ | Scheduled 6 Nov 2026 |
| "Hearts & Minds Ampersand" brand/identity | 2025–26 | New brand device referenced on website | Not detailed |
| 10-year anniversary campaign | May 2026 | Ten years of Hearts & Minds; target of ~A$100m donations in first ten years | A$96.1m cumulative (HM1 + conference) at FY26 |
ESG/sustainability commitments
Donation of 1.5% of NTA per annum to medical research (structural, ongoing). No emissions or climate targets disclosed.
Medium-term targets / guidance
No earnings, NTA or return guidance (the Directors state it is not possible or appropriate to predict performance). The only quantified forward commitments are (i) the 0.5c per half-year dividend increment, implying a 10.5c interim in April 2027 if maintained, and (ii) the 1.5% NTA donation rate.
Products & Services
Investor-facing offerings
| Offering | Description | Target user | Launch | Pricing |
|---|---|---|---|---|
| HM1 ordinary shares | ASX-listed exposure to concentrated global equity portfolio | Retail, SMSF, HNW, foundations | Nov 2018 | Market price; trades at a discount to NTA (12.7% to post-tax NTA at 30 Jun 2026) |
| Fully franked dividend stream | Half-yearly since FY2024; progressive +0.5c/half policy | Income/franking-sensitive investors | First dividend Apr 2021 | 20.0c annualised at FY26 (10.0c Oct 2026) |
| Dividend Reinvestment Plan (DRP) | Shares acquired on-market since 2024 (no dilution) | Long-term holders | Operational by FY2022 | Market-based DRP price |
| Weekly NTA and monthly investment updates | Transparency reporting to ASX | All shareholders | Since listing | Free |
| Investor hub (investors.hm1.com.au) | Q&A and comment platform | Shareholders | Referenced 2026 | Free |
| Sohn Hearts & Minds Investment Leaders Conference (affiliate) | Annual stock-pitch and philanthropy event; source of Conference Portfolio | Investors, industry | 2,016 | Ticketed (pricing not disclosed in sources reviewed) |
| Hearts & Minds Podcast / insights | Manager and researcher interviews | Public | ~2024 | Free |
Portfolio holdings — complete list at 30 June 2026 (the "product shelf")
| Holding | Exchange | Fair value (AUD) | % of portfolio | Sleeve / sponsor (where disclosed) |
|---|---|---|---|---|
| Taiwan Semiconductor (ADR) | NYSE | 67,248,315 | 7.9 | Core (named FY26 contributor) |
| ACM Research (Cl A) | Nasdaq | 63,073,709 | 7.4 | Conference 2025 — Beeneet Kothari, Tekne Capital (+283% since purchase) |
| Nvidia | Nasdaq | 41,923,344 | 4.9 | Core |
| Block (Cl A) | NYSE | 40,962,358 | 4.8 | Not disclosed (held since at least FY2024) |
| Brookdale Senior Living | NYSE | 40,849,837 | 4.8 | Conference 2025 — Vihari Ross, Antipodes |
| Amazon.com | Nasdaq | 36,402,771 | 4.3 | Core |
| Rokt Pte Ltd | Unlisted | 36,247,092 | 4.3 | Core (sole unlisted holding; carried at US$45/share) |
| Steel Dynamics | Nasdaq | 35,477,523 | 4.2 | Conference 2025 — Peter Rutter, Life Cycle Investment Partners |
| Live Nation Entertainment | NYSE | 32,676,953 | 3.9 | — |
| Royalty Pharma (Cl A) | Nasdaq | 32,408,063 | 3.8 | Core |
| Cameco | TSX | 31,472,038 | 3.7 | Core |
| SLB | NYSE | 31,438,942 | 3.7 | Conference 2025 — Robert Mullin, Marathon Resource Advisors |
| CK Hutchison (CKH Holdings) | HKSE | 30,514,885 | 3.6 | Core |
| Adidas | Xetra/DAX | 30,200,093 | 3.6 | — |
| Swire Pacific (A) | HKSE | 26,627,828 | 3.1 | Originally 2023 conference pick; current sponsor not disclosed |
| Guzman y Gomez | ASX | 26,287,500 | 3.1 | Core (pre-IPO investment Jan 2023) |
| AIA Group | HKSE | 25,933,092 | 3.1 | Originally 2023 conference pick; current sponsor not disclosed |
| Microsoft | Nasdaq | 25,008,861 | 3.0 | Core |
| CATL (H shares) | HKSE | 23,539,344 | 2.8 | — |
| Zillow Group (Cl C) | Nasdaq | 22,772,921 | 2.7 | Core |
| Puuilo | Helsinki | 20,748,659 | 2.4 | — |
| Monday.com | Nasdaq | 19,142,215 | 2.3 | Conference 2025 (presenter not specified) |
| SAP | Xetra/DAX | 17,913,295 | 2.1 | Core |
| Heidelberg Materials | Xetra/DAX | 15,700,622 | 1.9 | — |
| BlackLine | Nasdaq | 13,587,819 | 1.6 | Conference 2025 (presenter not specified) |
| DiDi Global (ADR) | OTC Pink | 12,779,423 | 1.5 | — |
| Morimatsu International | HKSE | 12,718,144 | 1.5 | — |
| Corporate Travel Management | ASX (suspended at 30 Jun 2026) | 0 | 0.0 | Conference 2024 — Rikki Bannan, IFM Investors (1,251,663 shares) |
| Cash and equivalents | — | 33,956,774 | 4.0 | — |
| Total portfolio | — | 847,612,422 | 100.0 | — |
Source: FY2026 Investment Committee Report; FNN (CTD sponsor). Analyst note: the step-up in Hong Kong exposure (HKD 1% at FY25 to 15% at FY26) coincides with Prusik's appointment as Asia ex-Japan Core manager in September 2025; holdings such as CATL and Morimatsu are plausibly Prusik ideas, but manager attribution is not disclosed.
Portfolio construction parameters
-
Holdings: FY2026 report cites 20–25 stocks typically; the website and FY2024/25 materials cite 25–35 (or 25–30). Discrepancy noted — the FY2026 annual report is the more recent primary source. Count at 30 June 2026: 27 securities with non-zero value plus CTD at zero.
-
Unhedged currency exposure (policy).
-
Fully invested subject to a cash buffer for tax, dividends, donations and expenses.
-
Unlisted exposure constrained (one holding, 4.3%).
Financial Narrative
Basis: Australian Accounting Standards / IFRS; A$; FY ends 30 June. Concepts such as gross profit, operating income and EBITDA have no standard LIC meaning; the closest analogues are presented and labelled.
Income statement
Sources: FY2024 and FY2026 Annual Reports (statements of comprehensive income; remuneration report five-year table). Margins and tax rate calculated. Gross profit, operating income and EBITDA as defined for trading companies: N/A (no cost of sales, no depreciation/amortisation, negligible interest expense — A$6 in FY2024, nil FY2026). Interest income was A$6,959 in FY2026.
Investment income CAGR (FY2023–FY2026): 11.2% p.a. (calculated). This figure is not economically meaningful given the volatility of mark-to-market income; NTA growth plus dividends is the appropriate measure.
Commentary. HM1's reported earnings track equity markets and manager selection. FY2022 was the inflection low: the growth- and technology-heavy portfolio built in 2020–21 fell sharply as rates rose, producing a A$219.6m comprehensive loss and cutting post-tax NTA from A$3.92 (FY2021) to A$2.81. The FY2023 rebuild (new CIO, new Core managers including Munro) drove a recovery through FY2024 and a record FY2025 (portfolio +25.5%, NPAT A$106.8m), powered by AI-linked holdings (Nvidia, TSMC), Guzman y Gomez's IPO and Rokt's revaluation. FY2026 earnings halved: a 5.2% pre-tax portfolio return was dragged by the "SaaSpocalypse" sell-off in application software (Zillow, SAP, Microsoft, Monday.com, BlackLine), Block and Guzman y Gomez weakness, AUD strength (unrealised FX loss of A$9.8m) and the write-off of CTD. Note that OCI (pre-October 2021 holdings) swung to a A$16.8m loss in FY2026 as legacy FVTOCI positions were realised at losses.
NTA, share price and per-share metrics
Sources: FY2024/FY2026 Annual Reports; FY2025 Annual Report summary (TSR 24%). FY2022 and FY2023 portfolio returns are derived from the FY2024 multi-period returns (2-year 13.4% p.a.; 3-year −5.1% p.a.) and are not directly reported figures. FY2023 TSR (18.1%) from InvestSMART (secondary). Discounts calculated; company reported FY2026 discount of 12.7% and FY2025 of 11.8% (minor rounding difference vs 11.6% calculated from A$3.04/A$3.44).
Balance sheet
Sources: FY2024 and FY2026 Statements of Financial Position and Changes in Equity; FY2022 cash from FY2023 cash-flow opening balance; FY2022 share capital and profits reserve from FY2024 Statement of Changes in Equity (1 July 2022 balances). Working capital calculated (current assets include FVTPL equities).
Commentary. HM1 is debt-free and has never used gearing. The balance sheet's main moving parts are the investment portfolio, the deferred tax liability on unrealised gains (which rose from A$5.9m to A$54.9m as the portfolio recovered, then eased to A$49.6m), and the current tax liability (A$15.9m at FY2026, reflecting heavy realised gains). Cash has been run down from A$122m (FY2022) to A$34m (FY2026, 4.0% of portfolio), consistent with the "fully invested" mandate. The profits reserve — the pool from which dividends are paid — jumped to A$201.1m (87.8c per share) after A$112.2m was transferred from retained earnings in FY2026.
Cash flow
Sources: FY2024 and FY2026 Statements of Cash Flows; Note 9(d). "Free cash flow" in the corporate sense is not meaningful for an LIC; dividends are funded by realising portfolio gains (investing cash flow).
Commentary. Portfolio turnover is high for a "high-conviction" vehicle: FY2026 sales of A$460.9m equate to ~59% of average portfolio value, reflecting the annual rotation of the 35% Conference sleeve plus Core changes. Rising tax paid (A$9.3m in FY2026 versus nil in prior years, after carried-forward losses were exhausted) replenishes the franking account and supports future franked dividends.
Ratios
Calculated from FY2024 and FY2026 Annual Reports. Net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle: N/A (no debt, no interest expense of significance, no inventory/receivables cycle). Payout is computed on cash dividends excluding DRP reinvestment.
Franking and dividend capacity
Source: FY2024 and FY2026 Note 3(f), Note 9. Analyst calculation: each 1.0c fully franked dividend (on 228.98m shares) consumes ≈A$0.98m of franking credits; A$33.2m available credits support ≈34c of fully franked dividends before new tax payments — about 1.7 years at the 20c annualised run-rate. Ongoing tax payments on realised gains are therefore essential to sustain the policy.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Sleeve Details
| Sleeve | Target weight | Composition | Holding period | Governance |
|---|---|---|---|---|
Core Portfolio | ~65% | Up to 20 securities; each Core Fund Manager supplies its three highest-conviction ideas, reviewed quarterly | Ongoing | CIO and Core Fund Managers monitor; Investment Committee oversees |
Conference Portfolio | ~35% | 10–15 securities pitched at the annual Sohn Hearts & Minds Conference, generally equal-weighted | Up to ~12 months, then rotated into next conference's picks | Conference Fund Manager Selection Working Group selects speakers |
Expense line (AUD Mn)
| Expense line (AUD Mn) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Donations to medical research | 10.09 | 10.09 | 11.25 | 11.52 |
Employee costs | 0.95 | 0.95 | 1.38 | 0.99 |
Other expenses (incl. interest) | 0.88 | 0.65 | 0.77 | 1.18 |
Total expenses | 11.92 | 11.69 | 13.41 | 13.69 |
Donations as % of total expenses | 84.6 | 86.3 | 83.9 | 84.1 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total investment income (AUD Mn) — "revenue" | — | 57.58 | 83.37 | 165.48 | 79.32 |
Total expenses (AUD Mn) | — | 11.92 | 11.69 | 13.41 | 13.69 |
Income before tax (AUD Mn) — EBIT/EBITDA proxy | — | 45.66 | 71.68 | 152.08 | 65.63 |
Income tax expense (AUD Mn) | — | 12.93 | 20.75 | 45.26 | 19.25 |
Net income after tax (AUD Mn) | — | 32.73 | 50.93 | 106.82 | 46.37 |
Other comprehensive income, net of tax (AUD Mn) | — | 30.23 | 2.53 | 17.97 | -16.82 |
Total comprehensive income (AUD Mn) | -219.59 | 62.95 | 53.45 | 124.78 | 29.55 |
Basic & diluted EPS (A cents) | — | 14.35 | 22.26 | 46.65 | 20.25 |
Dividends paid during year (A cents per share) | 13.5 | 13.5 | 14.0 | 15.5 | 18.5 |
Pre-tax margin (%) | — | 79.3 | 86.0 | 91.9 | 82.7 |
Net margin (%) | — | 56.8 | 61.1 | 64.5 | 58.5 |
Effective tax rate on P&L (%) | — | 28.3 | 28.9 | 29.8 | 29.3 |
Per-Share Data and Share Price
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Pre-tax NTA per share (AUD) | — | 2.90 | 3.09 | 3.71 | 3.67 |
Post-tax NTA per share (AUD) | 2.81 | 2.95 | 3.05 | 3.44 | 3.38 |
Share price at 30 June (AUD) | 2.02 | 2.26 | 2.58 | 3.04 | 2.95 |
Share price / post-tax NTA (x) | 0.72 | 0.77 | 0.85 | 0.88 | 0.87 |
Discount to post-tax NTA (%) | 28.1 | 23.4 | 15.4 | 11.6 | 12.7 |
Portfolio pre-tax return after expenses (%) | -33.9 | 15.1 | 11.7 | 25.5 | 5.2 |
Total shareholder return (%) | — | 18.1 | 20.0 | 24.0 | 3.1 |
Shares on issue (millions) | 227.85 | 228.80 | 228.98 | 228.98 | 228.98 |
Balance Sheet
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | — | 687.26 | 730.51 | 857.95 | 848.00 |
Cash and cash equivalents | 122.03 | 59.25 | 65.92 | 36.01 | 33.96 |
Financial assets at FVTPL | — | 479.95 | 553.56 | 767.64 | 783.75 |
Financial assets at FVTOCI | — | 129.23 | 94.08 | 54.07 | 29.90 |
Deferred tax assets | — | 17.97 | 9.74 | 0.00 | 0.00 |
Total liabilities | — | 11.74 | 33.10 | 71.25 | 74.11 |
Deferred tax liabilities | — | 5.91 | 19.52 | 54.89 | 49.64 |
Current tax liabilities | — | 0.00 | 0.00 | 7.88 | 15.91 |
Donation provision | — | 5.73 | 6.44 | 8.16 | 8.29 |
Total borrowings (short + long term) | 0 | 0 | 0 | 0 | 0 |
Net debt (cash negative = net cash) | -122.03 | -59.25 | -65.92 | -36.01 | -33.96 |
Shareholders' equity | 641.13 | 675.52 | 697.41 | 786.70 | 773.89 |
Share capital | 572.28 | 574.48 | 574.94 | 574.94 | 574.94 |
Profits reserve | 174.03 | 153.27 | 132.92 | 146.57 | 201.13 |
Goodwill & intangibles | 0 | 0 | 0 | 0 | 0 |
Working capital (current assets − current liabilities) | — | 534.24 | 613.11 | 787.52 | 793.63 |
Cash Flow
| Metric (AUD Mn) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Net operating cash flow | 7.60 | -3.30 | -2.55 | -13.14 |
of which donations paid | -10.24 | -9.37 | -9.54 | -11.38 |
of which income tax (paid)/refunded | 15.00 | 0.00 | 0.03 | -9.26 |
of which dividends received | 4.66 | 7.64 | 8.62 | 9.69 |
Net investing cash flow (sales less purchases) | -43.86 | 42.57 | 4.32 | 57.27 |
Proceeds from sale of investments | 444.41 | 332.52 | 412.18 | 460.90 |
Purchases of investments | 488.27 | 289.96 | 407.86 | 403.63 |
Capex | 0 | 0 | 0 | 0 |
Free cash flow (operating − capex) | 7.60 | -3.30 | -2.55 | -13.14 |
Dividends paid (cash) | 28.56 | 31.57 | 35.49 | 42.36 |
Dividends reinvested via DRP (non-cash) | 3.77 | 3.52 | 2.13 | 2.23 |
Share buybacks | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ROE — net income / avg equity (%) | 5.0 | 7.4 | 14.4 | 5.9 |
ROE — total comprehensive income / avg equity (%) | 9.6 | 7.8 | 16.8 | 3.8 |
ROA — net income / avg total assets (%) | — | 7.2 | 13.4 | 5.4 |
ROIC (%) — equal to ROE (no debt) | 5.0 | 7.4 | 14.4 | 5.9 |
Current ratio (x) | 92.7 | 46.2 | 49.1 | 33.4 |
Debt / equity (x) | 0 | 0 | 0 | 0 |
Total expenses / avg equity (%) | 1.81 | 1.70 | 1.81 | 1.75 |
Non-donation expenses / avg equity (%) | 0.28 | 0.23 | 0.29 | 0.28 |
Dividend payout (cash dividends / net income, %) | 87.3 | 62.0 | 33.2 | 91.4 |
Portfolio turnover (sales / avg investments, %) | — | 50.2 | 55.6 | 58.9 |
Dividends & Capital Returns
| Metric (AUD Mn) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Franking account closing balance | 54.40 | 41.29 | 26.06 | 17.27 |
Franking credits available for subsequent periods | 54.42 | 41.29 | 33.95 | 33.17 |
Franking credits used on dividends paid | 13.18 | 13.73 | 15.21 | 18.16 |
Profits reserve | 153.27 | 132.92 | 146.57 | 201.13 |
Revenue by Region (%)
| Currency exposure (% of portfolio) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
United States Dollar | 56 | 59 | 70 | 68 |
Hong Kong Dollar | 1 | 7 | 1 | 15 |
Euro | 10 | 3 | 8 | 10 |
Canadian Dollar | 3 | 6 | 5 | 4 |
Pound Sterling | 2 | 7 | 2 | 0 |
Australian Dollar (residual, calculated) | 28 | 18 | 14 | 3 |
Venue Details
| Venue | Weight (%) | Holdings |
|---|---|---|
Nasdaq (US) | 34.2 | ACM Research, Nvidia, Amazon, Steel Dynamics, Royalty Pharma, Microsoft, Zillow, Monday.com, BlackLine |
NYSE (US) | 25.1 | TSMC ADR, Block, Brookdale, Live Nation, SLB |
Hong Kong (HKSE) | 14.1 | CK Hutchison, Swire Pacific, AIA, CATL, Morimatsu |
Germany (Xetra) | 7.6 | Adidas, SAP, Heidelberg Materials |
Unlisted (Singapore-domiciled Rokt) | 4.3 | Rokt |
Cash | 4.0 | — |
Canada (TSX) | 3.7 | Cameco |
Australia (ASX) | 3.1 | Guzman y Gomez (CTD at zero) |
Finland (Helsinki) | 2.4 | Puuilo |
US OTC | 1.5 | DiDi Global |
Share Price History
| Period | Start price (AUD) | End price (AUD) | Change (%) | Basis |
|---|---|---|---|---|
1-year (30 Jun 2025 → 30 Jun 2026) | 3.04 | 2.95 | -3.0 | FY AR prices |
3-year (30 Jun 2023 → 30 Jun 2026) | 2.26 | 2.95 | 30.5 | FY AR prices |
5-year (30 Jun 2021 → 30 Jun 2026) | 4.32 | 2.95 | -31.7 | FY24/FY26 AR tables |
Since IPO (Nov 2018 → 30 Jun 2026) | 2.50 | 2.95 | 18.0 | FY26 AR |
Calendar 2026 YTD (to 11 Sep 2026) | 3.18 | 2.87 | -9.8 | InvestSMART (secondary) |
52-week range (to Sep 2026) | 2.65 | 3.51 | — | SmallCaps (secondary) |
Share price at 30 June (AUD)
| Share price at 30 June (AUD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
HM1 share price | 2.02 | 2.26 | 2.58 | 3.04 | 2.95 |
Post-tax NTA per share | 2.81 | 2.95 | 3.05 | 3.44 | 3.38 |
Valuation Multiples
| Multiple | HM1 | Basis |
|---|---|---|
P/E (trailing FY2026 EPS 20.25c) | 14.2x | Calculated |
P/E (FY2025 EPS 46.65c) | 6.2x | Calculated |
Price / post-tax NTA (A$3.38, 30 Jun 2026) | 0.85x | Calculated |
Price / pre-tax NTA (A$3.67) | 0.78x | Calculated |
EV (market cap A$657m − cash A$34m) | ≈A$623m | Calculated |
EV/EBITDA, EV/Sales | Not meaningful for an LIC | — |
Dividends paid (A cents per share)
| Dividends paid (A cents per share) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Fully franked dividends paid in year | 12.0 | 13.5 | 13.5 | 14.0 | 15.5 | 18.5 |
Payment date | Amount (c) | Type | Franking | — | — | — |
20 Apr 2021 | 12.0 | Annual | 100% | — | — | — |
12 Apr 2022 | 13.5 | Annual | 100% | — | — | — |
13 Apr 2023 | 13.5 | Annual | 100% | — | — | — |
19 Oct 2023 | 7.0 (derived) | Half-yearly | 100% | — | — | — |
18 Apr 2024 | 7.0 (derived) | Half-yearly | 100% | — | — | — |
17 Oct 2024 | 7.5 | Final | 100% | — | — | — |
17 Apr 2025 | 8.0 | Interim | 100% | — | — | — |
16 Oct 2025 | 9.0 | Final | 100% | — | — | — |
16 Apr 2026 | 9.5 | Interim | 100% | — | — | — |
15 Oct 2026 | 10.0 | Final (declared) | 100% | — | — | — |
Analyst Conclusions
Management guidance
No financial guidance is provided. The Board commits to (i) continuing fully franked dividends with half-yearly 0.5c increments, (ii) the 1.5% NTA donation, (iii) narrowing the discount to NTA, and (iv) enhancing risk management via Plato's screen. The Directors note performance depends on investee and macro factors and cannot be predicted.
Consensus expectations
No analyst consensus exists. Mechanically, the dividend policy implies 10.5c (Apr 2027) and 11.0c (Oct 2027), i.e., ≈21.5c over the next 12 months versus 20.0c annualised today.
Bull case
-
Discount re-rating: at 0.85x post-tax NTA, closing half the 12.7% discount alone would deliver ~6–7% upside before portfolio returns, and the Board has publicly committed to narrowing it.
-
Recoveries and catalysts embedded in NTA: CTD's return to trading (carried at zero at FY2026) and a potential Rokt liquidity event (A$36.2m, held flat at US$45) offer asymmetric NTA upside.
-
Yield support: 7.0% cash yield (≈10% grossed-up) backed by A$201m profits reserve and A$33m franking credits, plus rising tax payments replenishing franking.
Bear case
-
Persistent alpha deficit: underperformance versus MSCI World in FY2024 and HY2026 undermines the active proposition when ETFs cost a fraction of HM1's ~1.75% all-in expense ratio (including donations).
-
Process risk: two write-to-zero events reported in 2025 and high portfolio turnover (~59%) suggest uneven idea quality; the Plato overlay is untested.
-
Governance/structure: related-party donation concentration (43% to one director-linked institute), leadership churn, and a retail register that limits activist pressure could keep the discount entrenched.
Key catalysts and monitorables (next 12 months)
| Date / timing | Catalyst | What to watch |
|---|---|---|
| 15 Oct 2026 | 10.0c dividend payment | DRP participation |
| 6 Nov 2026 | Queenstown Sohn Hearts & Minds Conference | Quality and sector mix of 10–15 new picks |
| 19 Nov 2026 | AGM | Discount-management measures (buyback?), Plato rollout detail, board renewal/diversity |
| Ongoing (weekly) | NTA estimates | CTD valuation post-relisting; FX moves |
| Q4 2026–2027 | Rokt | Any IPO, funding round or revaluation |
| Feb 2027 | HY2027 results | Interim dividend 10.5c per policy; performance vs MSCI World |
| 2,027 | Core manager panel | Further changes after Prusik; manager attribution transparency |
| 2,027 | Franking balance | Tax paid vs dividend franking usage |
Analyst verdict
Hearts and Minds Investments is a genuinely differentiated vehicle: a debt-free, fee-free (to managers) global equity portfolio whose cost structure is redirected to Australian medical research, governed by an unusually experienced and unpaid board. Its financial position is robust — A$774 million of net assets, no borrowings, a profits reserve of roughly 88 cents per share and enough franking to support the progressive dividend for well over a year even without fresh tax payments. Over three years to June 2026 the portfolio compounded at 13.8% per annum, and the dividend has risen from 13.5 cents to a 20-cent annual run-rate.
The difficulty is that investors have not been rewarded commensurately. The shares have traded below post-tax NTA continuously since the FY2022 drawdown, and the most recent period exposed process weaknesses: a flat first half of FY2026 against a 9% market gain, a high-profile write-off of Corporate Travel Management, and exposure to both sides of the AI trade. Leadership churn in 2024–25 and the concentration of donations in a director-linked institute are governance points that a premium-rating LIC would typically have resolved.
On balance, HM1 screens as a value-and-income proposition rather than a growth story: at about 0.85 times post-tax NTA with a 7% fully franked yield, the price already discounts mediocre stock selection, while CTD's relisting, a possible Rokt event and the Plato risk overlay offer upside optionality. The decisive variables are execution of the new risk framework, the quality of the Queenstown conference picks, and whether the Board backs its stated commitment to narrowing the discount with concrete capital management. Absent such action, the discount is likely to persist, and returns will track a volatile, concentrated portfolio plus the dividend. Investors who value the philanthropic dimension may reasonably accept that trade-off; purely return-focused investors should demand evidence of sustained benchmark outperformance first.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education | FY2026 total remuneration (AUD) |
|---|---|---|---|---|---|
Richard Howes | Managing Director (part-time) and Director | Since 1 Jun 2025 | Group CEO & MD, Challenger Limited; 19 years at Challenger incl. CIO and CEO of annuity business; Zurich Capital Markets, Macquarie, Bankers Trust; QIC strategy | B.Com (Hons) and Economics, University of Queensland; Harvard AMP | 237,500 (fees under services agreement; no super, no equity, no incentive) |
Charlie Lanchester | Chief Investment Officer | Since 12 Apr 2023 | Head of Fundamental Australian Active Equities, BlackRock; Perpetual, Platinum, Schroders | — | 250,500 (A$225,000 fixed + A$25,500 superannuation) |
Natalie Climo | Company Secretary (Boardroom employee) | Appointed after Feb 2024 (exact date not disclosed in sources reviewed) | Governance professional and lawyer | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| KMP remuneration (AUD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total KMP remuneration | 501,000 | 781,871 | 609,891 | 1,092,353 | 488,000 |
Board of Directors
| Director | Role | Appointed | Background | Other notable roles | HM1 shares (30 Jun 2026) |
|---|---|---|---|---|---|
Christopher Cuffe AO | Chair, Independent | 12 Sep 2018 | CEO Colonial First State (1990–2003); CEO Challenger Group (2003); chartered accountant | Director, Staude Capital Global Value Fund; Third Link Growth Fund founder/PM | 150,000 |
Lorraine Berends AM | Independent; Chair, Investment Committee | — | 15 years at Marvin & Palmer; former Chair of CIMA Society and ASFA; FIAA | NED Pinnacle Investment Management, Plato Income Maximiser, Spheria Emerging Companies | 45,000 |
Guy Fowler OAM | Independent; co-founder | Oct 2018 | 25+ years UBS (Head of Capital Markets, Corporate Advisory); founder & Co-Executive Chair Barrenjoey | — | 1,426,211 |
Matthew Grounds AM | Independent; co-founder; IC member | — | UBS ANZ CEO for 11 years; Joint Global Head of IB; Co-Executive Chair Barrenjoey | Chairman, Victor Chang Cardiac Research Institute | 1,260,959 |
Michael Traill AM | Independent | — | Founding CEO Social Ventures Australia; co-founder Macquarie Direct Investment | Executive Chair For Purpose Investments; Chair of Paul Ramsay Foundation until 30 Jun 2026 | 72,281 |
Gary Weiss AM | Independent; co-founder | — | Former Chair Coats PLC, Estia Health, ClearView; ex-Guinness Peat | Exec Director Ariadne; Chair Coast Entertainment, Cromwell; Interim Chair Webjet (May 2026); Deputy Chair Myer; NED Straits Trading (Apr 2026), Thorney Opportunities, Victor Chang Institute | 507,846 |
Geoffrey Wilson AO | Independent | — | Founder Wilson Asset Management (A$6bn+, 130,000 investors) | Chair of eight WAM LICs; founder/director Future Generation Australia, Global and Women | 1,687,500 |
David Wright | Independent; IC member | — | Co-founder and former CEO Zenith Investment Partners | Head of Client Solutions, Pinnacle Investment Management | 106,239 |
Richard Howes | Managing Director | 1 Jun 2025 | See 9.1 | UTS Council; Edge Zero board | 105,000 |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Feb 2023 | CIO Rory Lucas departs | Portfolio management overhaul |
12 Apr 2023 | Charlie Lanchester appointed CIO | Ex-BlackRock |
21 Feb 2024 | Company Secretary Tom Bloomfield resigns; Eryl Baron appointed | Boardroom personnel change |
5 Dec 2024 | CEO Paul Rayson announces retirement (effective 19 Feb 2025); Brett Jollie appointed | Founding CEO since 2018 |
19 May 2025 | Jollie to step down 30 Jun 2025 after ~6 months; part-time MD model adopted | Board cited Jollie's operating-model review and portfolio-management automation as enabling a leaner structure; no departure reason given |
1 Jun 2025 | Richard Howes appointed MD and director | Former Challenger CEO |
By Aug 2026 | Natalie Climo is Company Secretary | Boardroom employee |
Governance Detail
| Victor Chang Cardiac Research Institute donations | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Donation to Victor Chang Institute (AUD Mn) | 5.04 | 4.14 | 4.50 | 4.96 |
Share of total donations expense (%) | 49.9 | 41.0 | 40.0 | 43.1 |
Competitive Landscape
Key Competitors
| Competitor | Ticker | Category | Relative positioning vs HM1 |
|---|---|---|---|
Future Generation Global Investment Company | FGG | Philanthropic global LIC (pro bono managers, 1% of NTA donated) | Most direct model peer; founded by HM1 director Geoff Wilson; fund-of-managers rather than direct stock picks |
Future Generation Australia | FGX | Philanthropic Australian-equity LIC | Same philanthropic model, domestic focus |
WAM Global | WGB | Global LIC (Wilson Asset Management) | Fee-charging; mid-cap global focus; Wilson-linked |
MFF Capital Investments | MFF | Concentrated global LIC | Larger, concentrated quality portfolio; strong long-term record |
Magellan Global Fund (closed class) | MGF | Global listed fund | Magellan is also an HM1 Core manager |
Platinum Capital | PMC | Global LIC | Value/contrarian; style contrast |
Pengana International Equities | PIA | Global LIC | Fee-charging global ethical/quality |
Regal Investment Fund | RF1 | Alternatives listed trust | Regal was formerly an HM1 Core manager |
L1 Long Short Fund | LSF | Long/short listed fund | Competes for HNW active allocations |
Global equity ETFs (e.g., Vanguard, iShares MSCI World products) | VGS, IVV, IOO | Passive | Ultra-low fees; HM1's FY24 and HY26 underperformance vs MSCI World strengthens passive alternative |
Peer Comparison FY2026
| Metric | HM1 | MSCI World (AUD) | Notes |
|---|---|---|---|
FY2024 return (%) | 11.7 | 18.3 | FY24 AR |
2-year return to FY2024 (% p.a.) | 13.4 | 19.5 | FY24 AR |
3-year return to FY2024 (% p.a.) | -5.1 | 9.3 | FY24 AR |
Since inception to FY2024 (% p.a.) | 9.3 | 11.8 | FY24 AR |
HY2026 return (%) | 0.4 | 9.2 (Accumulation) | HY26 announcement (secondary) |
Since inception to FY2026 (% p.a.) | 10.7 | Not disclosed in FY26 AR | FY26 AR dropped benchmark comparison |
Recent Developments
--



